Source legit

Growth hormone releasing peptides protocol log

Our Terms

Mechanism, dose window, half-life, stack pairing, sourcing pathway. The sermorelin entry, plus adjacent GHRPs and GHRH analogs adults actually run.

Start your consultation

These are the terms under which makes the editorial reference at sermorelin-peptides.com available to readers. By using the site you agree to read content within the framing that it is provided.

Acceptance

Opening any page on this site counts as acceptance of the terms below. If you do not agree with a clause the right course of action is to stop using the site.

What the site is

is an editorial reference about growth hormone releasing peptides, their pharmacology, the regulatory environment that covers compounded preparations in the United States, and the lawful pathways through which a clinician may prescribe these molecules to a patient. Articles are written by editors who read primary literature and regulatory documents. The pages are educational, not transactional.

Intellectual property

Article copy, page layouts, photographs produced for us, diagrams and the underlying selection of topics on this site are the work of and its contributors. Copyright in the original elements remains with the editorial team unless an explicit license is granted. Short quotations with attribution are welcome under standard fair-use conventions. Wholesale republication is not permitted without prior written consent.

Trademarks of third parties referenced in our coverage remain the property of their owners. We mention compound names and brand names only where they are needed to explain a topic.

No warranty around health information

The site discusses pharmacology and regulation. We do not warrant that any specific statement applies to your circumstances, your physiology, your medications or your medical history. Nothing on the site replaces a consultation with a licensed clinician. The content is provided on an as-is basis without warranty of any kind, including fitness for a particular medical purpose, accuracy, completeness, or non-infringement of third-party rights.

If you act on something you read here without first speaking with a qualified healthcare professional, you are doing so at your own risk.

Limit of liability

To the maximum extent permitted by applicable law, , its editors, contributors and operators are not liable for any direct, indirect, incidental, consequential or punitive damages arising from your access to or use of the site, your reliance on any content, or your inability to access the site. This limit applies whether the claim is framed as contract, tort, statute or any other theory.

External links

The site links to regulator pages, primary literature, monographs, and other publishers. We do not control those destinations. A link is not an endorsement and we are not responsible for the content, accuracy or privacy practices of any external site.

User-submitted content

If you send us a message through the contact form you grant the right to read it, reply to it, retain it for internal records, and refer to its substance in editorial work in a manner that does not identify you. Do not send confidential information or personal health data through the form.

Governing law

These terms are governed by the laws of the jurisdiction in which is established, without regard to its conflict-of-laws principles. Any dispute that cannot be resolved by correspondence will be brought before the courts of that jurisdiction.

Modifications

We update these terms as the operation of the site evolves. The version published at the URL you are reading now is the version in force. Continued use after a change counts as acceptance of the revised wording.

Sermorelin, profile entry in the United States, USA

A 29 amino acid GHRH analog that binds the same pituitary receptor as endogenous growth hormone releasing hormone. Triggers a physiologic pulse of growth hormone in the body's own pattern, while the natural negative feedback loop stays intact. Approved branded form discontinued. For adults across the United States, USA, modern administration is compounded, prescription only, from US 503A and 503B pharmacies.

Dark laboratory shelf with sermorelin peptide vials lit by a thin lime accent

Mechanism

Binds pituitary GHRH receptor, triggers pulsatile GH release. Feedback loop preserved.

Dose window

100 to 500 mcg subcutaneous nightly. Most US telehealth protocols sit at 200 to 300 mcg.

Cycle length

12 weeks standard. Re-evaluate IGF-1 at week 12. Off-cycle 4 to 8 weeks if continuing.

Lab markers

IGF-1, fasting glucose, HbA1c, lipids, basic metabolic panel.

Common stack

Sermorelin GHRH plus ipamorelin GHRP for synergistic pulse amplification.

Side effect floor

Injection site redness, transient flush, occasional headache. Hypoglycemia screened.

Adjacent peptides commonly stacked

Sermorelin rarely runs alone in serious protocols. The two adjacent classes worth understanding are GHRPs, which amplify GH pulse amplitude, and longer half-life GHRH analogs, which extend the pulse window. The table below summarizes the field. None of these are sold legally without prescription in the US.

Molecular wireframe visualization of growth hormone releasing peptides on a dark screen
PeptideClassHalf lifeTypical role
SermorelinGHRH analog10 to 20 minRestore natural overnight pulse
TesamorelinGHRH analog, modified26 min in serumStronger pulse, FDA approved for HIV lipodystrophy
CJC 1295 with DACGHRH analog, long actingDays, not minutesSustained elevation, loses pulsatility
IpamorelinGHRP, selective2 hoursPulse amplification, minimal cortisol or prolactin
GHRP 2GHRP1 to 2 hoursPulse amplification, mild appetite increase
HexarelinGHRPApprox 1 hourStrong pulse but blunts response over time, rarely used long term

The cycle protocol

A standard 12 week sermorelin run looks like the schedule below. Adjust dose by clinician, not by self-titration. The five-on-two-off cadence reduces tachyphylaxis at the pituitary GHRH receptor over a long cycle.

WeekDoseCadenceLab checkNotes
1 to 4200 mcg5 on, 2 offBaseline IGF-1 doneSleep depth shifts first. Hold steady.
5 to 8200 to 300 mcg5 on, 2 offNone mid cycleSkin, hair, energy. Training recovery up.
9 to 12300 mcg5 on, 2 offFollow up IGF-1 at week 12Body composition window. Reassess.
Week 13Pause or maintainClinician callCompare IGF-1 to baselineDecide hold, lower, or cycle off 4 to 8 weeks.

Sourcing pathway in the United States

There are two channels for sermorelin in the US. One is legal, clinical, and traceable. The other is not, and is sold under a research-only label that buyers routinely ignore. The difference matters for purity, dose accuracy, and personal legal exposure.

Dark lab interface dashboard showing IGF-1 and protocol tracking data

Clinical pathway

Compounded prescription

  • Online consultation with a licensed clinician in your state
  • Baseline IGF-1 plus metabolic panel ordered
  • Prescription dispensed by a 503A or 503B compounding pharmacy
  • Sterile vial, accurate concentration, traceable batch
  • Sharps kit, dosing protocol, follow-up labs

View licensed provider

Research-only pathway

Grey market peptide vendor

  • Sold as research chemical, not for human consumption
  • No clinician oversight, no prescription, no liability
  • Purity and dose vary by batch and supplier
  • No medical record, no lab follow-up
  • Federal grey area for buyer, frank illegal for some sellers

Not recommended for any adult running protocols seriously.

Self-tracking log, what to measure

Sermorelin works on a slow curve. The signal arrives over weeks, not days, and shows up unevenly across markers. The tracking spec below catches the typical response without over-instrumenting.

Top down view of lab equipment, micropipettes and small vials on a matte black surface

  • Sleep depth, weeks 1 to 4

    Wearable deep sleep minutes, subjective restfulness on waking. Most consistent first signal.

  • Morning energy, weeks 1 to 4

    Subjective on a 1 to 10 scale at the same time each morning. Daily, no trend smoothing the first month.

  • Training recovery, weeks 4 to 8

    Time to feel ready for the next session after a hard lift or run. Notes on DOMS duration.

  • Body composition, weeks 8 to 12

    Same day of week, same time of day, same equipment. Waist circumference and weight at minimum. DEXA if possible at baseline and end.

  • IGF-1, week 12

    Follow up draw. Compare to baseline. This is the only objective biochemical signal the protocol moves predictably.

  • Fasting glucose, monthly

    Safety marker. GH downstream can shift insulin sensitivity. Flag any sustained rise.

Source it through a US licensed clinic in the United States, USA

Compounded sermorelin from a registered pharmacy, after a real consultation and lab with a US-licensed clinician. Refund if the clinician says no.

Start your consultation